MX2024009650A - Sal cristalina y formas de solvato de murizatoclax (amg 397). - Google Patents

Sal cristalina y formas de solvato de murizatoclax (amg 397).

Info

Publication number
MX2024009650A
MX2024009650A MX2024009650A MX2024009650A MX2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A MX 2024009650 A MX2024009650 A MX 2024009650A
Authority
MX
Mexico
Prior art keywords
solvate forms
amg
salt
murizatoclax
crystalline salt
Prior art date
Application number
MX2024009650A
Other languages
English (en)
Spanish (es)
Inventor
Mary Chaves
Robert P Farrell
Stephan Parent
Jing Teng
Lingyun Xiao
Ron C Kelly
Darren L Reid
James E Huckle
Tian Wu
Michal Achmatowicz
Van Luu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2024009650A publication Critical patent/MX2024009650A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2024009650A 2022-02-04 2023-02-03 Sal cristalina y formas de solvato de murizatoclax (amg 397). MX2024009650A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306781P 2022-02-04 2022-02-04
PCT/US2023/012252 WO2023150250A1 (en) 2022-02-04 2023-02-03 Crystalline salt and solvate forms of murizatoclax (amg 397)

Publications (1)

Publication Number Publication Date
MX2024009650A true MX2024009650A (es) 2024-08-14

Family

ID=86054183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009650A MX2024009650A (es) 2022-02-04 2023-02-03 Sal cristalina y formas de solvato de murizatoclax (amg 397).

Country Status (7)

Country Link
US (1) US20250122224A1 (cg-RX-API-DMAC10.html)
EP (1) EP4472985A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505142A (cg-RX-API-DMAC10.html)
AU (1) AU2023215171A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248348A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024009650A (cg-RX-API-DMAC10.html)
WO (1) WO2023150250A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119255998A (zh) 2022-05-04 2025-01-03 吉利德科学公司 特定mcl-1抑制剂的盐和多晶型物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
JP7873057B2 (ja) * 2020-03-31 2026-06-11 アムジエン・インコーポレーテツド Mcl-1化合物のメチル化

Also Published As

Publication number Publication date
US20250122224A1 (en) 2025-04-17
JP2025505142A (ja) 2025-02-21
CA3248348A1 (en) 2023-08-10
AU2023215171A1 (en) 2024-07-04
EP4472985A1 (en) 2024-12-11
WO2023150250A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
DOP2021000216A (es) Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
PE20221762A1 (es) Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos
EP4647129A3 (en) PROCESS FOR PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A!PYRROLO[2,3-E!PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID FORMS THEREIN
UY27380A1 (es) Compuestos de heteroarilo bicíclicos fusionados sustituidos con heteroarilo como ligandos del receptor gabaa
HUT74679A (en) K-252a indolocarbazole alkaloid derivatives which enhance neurotrophin-induced activity
TW200738660A (en) Piperidinyl derivatives as modulators of chemokine receptor activity
ES2178668T4 (es) Naftilamidas como agentes del sistema nervioso central.
EE9900079A (et) Meetod 21-atsüüloksüpregna-1,4-dieen-11ß,16a,17a-triool-3,20-diooni derivaatide 16,17-atsetaalderivaatide R-epimeerseks rikastamiseks
ES2078405T3 (es) Procedimiento para la purificacion de insulinas por cromatografia.
MX2024009448A (es) Formas cristalinas de un inhibidor de mcl-1.
ES2054723T3 (es) Tetrahidropiridinoximas, procedimiento para su preparacion y uso de las mismas como agentes colinergicos.
AU2016211630A1 (en) Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
BRPI0509514A (pt) métodos para a preparação de (3r,3as,6ar)-hexaidro-furo[2,3-b]-furan-3-ol
IL272652B (en) A pentacyclic compound, the pharmaceutical compounds that make it up and their use for the treatment of Alzheimer's disease
UY25501A1 (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo [4.3.0]nonano
Baxter et al. Some studies on the convulsant action of folic acid
MX2025012360A (es) Derivados de pirrolopiridina como moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
Cabral-Miranda et al. Astrocytic proteostasis in the tale of aging and neurodegeneration
Zhang et al. Inhibition of astroglial hemichannels ameliorates infrasonic noise induced short-term learning and memory impairment
Norambuena et al. Language, analogical reasoning, and working memory skills in emergent literacy period: Typical and DLD trajectories via Cluster Analyses
MX2025012362A (es) Derivados de 1,6-naftiridina como moduladores alostericos positivos del receptor muscarinico de acetilcolina m4, utiles para el tratamiento de trastornos neurologicos y psiquiatricos
CY1125134T1 (el) Ενωσεις 1,2,3',5'-τετραϋδρο-2'h-σπειρο[ινδολο-3,1'-πυρρολο[3,4-c]πυρρολο]-2,3'-διονης ως θεραπευτικοι παραγοντες που ενεργοποιουν τρ53
MX2024012192A (es) Formas de sal y solvatos de antagonistas de mci-1
Perovic et al. The effect of age on language in adults with intellectual disabilities: A comparison of passives in Down syndrome and Williams syndrome
Ross et al. A simple eyelid conditioning masking task and its effect on differential conditioning